Eric Benevich - 28 Nov 2025 Form 4/A - Amendment Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: NBIX
Reported as of: 28 Nov 2025
Net transaction value: +$461,752
SEC form: 4/A - Amendment
Accepted by SEC: 16 Jan 2026, 17:17:59 UTC
Original report date: 02 Dec 2025
Prior SEC filing: 02 May 2025
Next SEC filing: 03 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Eric Benevich filed Form 4/A - Amendment for NEUROCRINE BIOSCIENCES INC (NBIX) on 16 Jan 2026.

Key facts

This page summarizes Eric Benevich's Form 4/A - Amendment filing for NEUROCRINE BIOSCIENCES INC (NBIX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jan 2026, 17:17.

Change

Previous filing in this sequence was filed on 02 May 2025.
Current net transaction value: +$461,752.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001643653 Primary reporting owner

BENEVICH ERIC

Relationship: Chief Commercial Officer
Address: 6027 EDGEWOOD BEND CT., SAN DIEGO
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Signature date: 16 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Options Exercise

Transaction value: $461,752
Shares: +12,830
Change %: +29%
Price: $35.99
Shares after: 57,723
Date: 28 Nov 2025
Ownership: Direct
Footnotes: F1, F2

NBIX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 51,753
Date: 28 Nov 2025
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBIX transaction Derivative

Incentive Stock Option

Options Exercise

Transaction value: $0
Shares: -12,830
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,830
Exercise price: $35.99
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options.

Footnote F2

Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Footnote F3

This line is included solely to report the Reporting Persons corrected beneficial ownership of Common Stock in Column 5 following the November 28, 2025 transactions previously reported in the Form 4 filed on December 2, 2025.

Footnote F4

The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026.